VANCOUVER, BC – (GLOBE NEWSWIRE) – May 31, 2021 – Avricore Health Inc. (TSXV:
AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce the signing
of a supplier distribution agreement between HealthTab™ Inc., a wholly owned subsidiary, and
Abbott, the global healthcare company and diagnostics leader, in Canada.
This agreement allows the Company to distribute in Canada Abbott’s Afinion™ 2 and
associated tests for diabetes and heart-disease screening in community pharmacies, including
HbA1c testing, a critical marker for the screening and management of diabetes.
“Diabetes affects millions of Canadians and early detection is key to avoiding the most serious
of impacts of the disease,” said Hector Bremner, CEO of Avricore Health. “We’re excited to
expand our testing capabilities to offer more ways to screen and manage diabetes in community
pharmacy.”
HealthTab™ continues its work in adding more tests and instruments to the platform, expanding
its offering to enhance community pharmacies capabilities with respect to point-of-care testing.
Facts About Diabetes in Canada
According to Diabetes Canada, nearly 30% of Canadians live with diabetes or prediabetes with
many undiagnosed. The disease is believed to reduce lifespan by up to 15 years in those
affected by significantly contributing to heart attack and stroke risk, as well as other serious
chronic disease. Learn more about diabetes in Canada here.
About HealthTab™ + RASTR
HealthTab™ is a proven point-of-care screening system, designed to support pharmacists
evolving role. The system empowers patients to be proactive about their health by directly
measuring and monitoring key safety tests and biomarkers of chronic disease. The HealthTab™
test is simple, fast, lab-accurate, and requires just a few drops of blood from a finger stick.
Results can be printed in-store or accessed securely online.
As part of this direction for HealthTab™, the Company developed a revolutionary model for
utilizing the system’s unique ability to offer real-time evaluations of treated populations and even
real-world evaluation clinical trials.
The name for this approach is Rapid Access Safety Test Reporting, or RASTR Network,
whereby the network of HealthTab™ systems feedback de-identified data through to electronic
health records and data management systems via its API capabilities. This is the first platform
of harmonized analyzers, with fully integrated data-flow, for blood chemistry results to be sent to consumers, their healthcare teams and sponsors; such as researchers, insurance providers and the life-science sector.
The significance of this approach to the market is the enhanced access to screening and early
detection of disease, better data for physicians and pharmacists to support their patients, plus
new opportunities to conduct research and ensure patient safety.
About Avricore Health Inc.
Avricore Health Inc. is committed to becoming a health innovator and applying technologies at
the forefront of science to core health issues at the community pharmacy level. The Company's
goal is to empower consumers, patients and pharmacists with innovative technology, products,
services and information to monitor and optimize health. www.avricorehealth.com
Contact:
Hector Bremner, CEO 604-773-8943
[email protected]
Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company’s expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health’s management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore’s public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy.
